FDA Compassionate Use: How to Request Exceptional Access
Navigating critical medical situations often necessitates unprecedented measures, and in some cases, this leads to requests for compassionate use of unapproved medications. A "compassionate use" or " Expanded Access" request is a process by which patients with life-threatening or serious diseases or conditions may access investigational drugs outside of a clinical trial. The U.S. Food and Drug Administration (FDA) plays a pivotal role inthese requests, reviewing and approving or denying them based on extensive medical evaluations.
Understanding the FDA's compassionate use request process is essential for patients, healthcare providers, and institutions seeking such access. This article provides an in-depth look into the process, its criteria, application, and what to expect. By understanding these critical steps, you can better navigate the complex landscape of obtaining early access to potentially lifesaving treatments.
Understanding FDA's Compassionate Use Request
The FDA's Expanded Access program, previously known as compassionate Use, allows patients with serious conditions to use non-approved treatments outside of clinical trials. It's a last-resort option for patients who have exhausted all available approved treatments and have a life-threatening disease or medical condition.
The FDA evaluates each request on a case-by-case basis, considering the potential benefit to the patient, the safety of the drug, and the availability of the treatment. If approved, the FDA will facilitate the company's release of the investigational product to the healthcare provider for treatment.
Types of requests
The FDA receives two kinds of requests for expanded access: individual patient expanded access requests and intermediate-size patient access requests. Individual patient requests involve a single patient, while intermediate-size requests cover between one and fewer than 20 patients.
Additionally, the FDA has a parallel track program for late-stage condidtion n where a drug is being reviewed for approval but has not yet received it. This program allows patients to access the drug while the FDA reviews the corresponding New Drug Application (NDA).
Eligibility criteria
The FDA has established certain criteria to determine a patient's eligibility for expanded access. The patient must have a serious disease or condition, or be in serious distress, and have no other adequate treatment options available. Furthermore, there must be preliminary evidence that the drug may provide a benefit to the patient, and there should be no concerns about safety.
Past participation in a clinical trial studying the same drug is not a barrier to application. However, the patient must provide informed consent and understand the potential risks and benefits of the treatment, as well as the fact that the drug is investigational and not approved by the FDA for their condition.
Submitting an Expanded Access Application
Submitting an expanded access application involves several steps, beginning with finding a sponsor, who can be a pharmaceutical company or a company willing to facilitate the treatment. The healthcare provider then submits a proposal to the sponsor, detailing the patient's medical history, the condition, and the rationale for using the drug.
The sponsor then submits the request to the FDA, along with a questionnaire, a detailed description of the drug, and evidence supporting the drug's use in the patient's condition. The FDA reviews the request and responds within 15 days to the sponsor, who then shares the response with the healthcare provider.
What to expect after submission
After submission, the FDA may request additional information from the sponsor, who should provide it promptly to facilitate a quick decision. The FDA may also consult with its external experts to help assess the request, such as the Oncologic Drugs Advisory Committee or other relevant expert groups.
Once the FDA has all the necessary information, it will approve or deny the request. If approved, the company will release the drug to the healthcare provider for treatment. If denied, the FDA will explain the reasons for the denial, and the healthcare provider or sponsor may request reconsideration if new information becomes available.
Monitoring and follow-up
After the initiation of treatment under expanded access, healthcare providers should monitor the patient's progress and report adverse events to the FDA. The FDA may also contact healthcare providers to check on the patient's status and whether they continue to receive benefit from the treatment.
Moreover, the FDA may require the sponsor to report treatment data periodically to gain insight into the effectiveness of the drug in this new patient population. This data can help refine the drug's plan for future studies or, eventually, market approval.
In navigating the complex landscape of expanded access, it is crucial to remember that it is a stop-gap measure, aiming to provide a glimmer of hope to patients with life-threatening or serious diseases. While not all applications will be approved,commitment to exploring all available treatment options significantly enhances patients' chances of survival and improved quality of life.